Search Results - robert+prins

4 Results Sort By:
Identification of a Platform to Identify Tumor-Specific T Cell Receptors (UCLA Case No. 2022-082)
SUMMARY: Researchers from UCLA’s Department of Neurosurgery and Pharmacology have developed a rapid discovery platform for the identification of tumor-specific T cell receptors to aid in more personalized and potent immunotherapy for glioblastoma. BACKGROUND: Over the past several years, immunotherapy, or therapies that enlist and strengthen...
Published: 5/20/2024   |   Inventor(s): Robert Prins, Alexander Lee, Lu Sun, David Nathanson
Keywords(s):  
Category(s): Therapeutics, Therapeutics > CNS and Neurology, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy
Targeted Neoantigen Vaccination in H3G34R/V Glioma (UCLA Case No. 2021-008)
UCLA researchers in the Departments of Neurosurgery and Microbiology, Immunology, and Molecular Genetics have developed an immunotherapy treatment methodology for H3G34R/V high-grade glioma, providing an ability to be adapted toward a wide range of similar tumors.BACKGROUND:Over 3000 gliomas and other forms of brain cancer are diagnosed in children...
Published: 5/4/2024   |   Inventor(s): Anthony Wang, Geoffrey Owens, Yi Xing, Robert Prins, Linda Liau, David Nathanson
Keywords(s): Immunotherapy, Oncology, Oncology Immunotherapy
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy
2015-341 COMBINATIONS OF CHECKPOINT INHIBITORS AND DENDRITIC CELL VACCINES TO TREAT BRAIN CANCER
UCLA researchers in the Departments of Neurosurgery and Molecular and Medical Pharmacology have developed an autologous dendritic cell (DC) vaccine in combination with checkpoint inhibitors for the treatment of malignant brain tumors.BACKGROUND: Checkpoint inhibitor therapies, which unblock an existing immune response, or unblock the initiation of an...
Published: 7/19/2023   |   Inventor(s): Robert Prins, Linda Liau
Keywords(s): Antibodies, Drug Delivery, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), Oncology Immunotherapy, Therapeutics & Vaccines, Vaccines
Category(s): Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)
Identification of a Platform for T Cell Receptor Recognition of Splice Variation Neoantigens in Glioblastoma (UCLA Case No. 2019-693)
UCLA researchers in the Departments of Neurosurgery and Pharmacology have developed a novel platform for the identification of alternative splice variants unique to cancer cells, for use as neo-epitope vaccines or as T cell Receptor-based cell therapy of brain cancer. BACKGROUND:T cells are a type of lymphocyte that play a central role in immune response...
Published: 5/20/2024   |   Inventor(s): Robert Prins, Yi Xing
Keywords(s): Diagnostic Markers & Platforms, Oncology, Therapeutics & Vaccines
Category(s): Diagnostic Markers, Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy